Infliximab, a TNF-α antibody that blocks TNF-α receptor interactions has shown promise in the treatment of rheumatoid arthritis, as has Etanercept, an agent that binds with TNF-α preventing from interacting with its receptor. The gene discussed is TNF; the disease is rheumatoid arthritis.